Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients

NACompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Vitamin B12 Deficiency
Interventions
DRUG

Vitamin B12

Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.

Trial Locations (1)

10305

Island Rehab, Staten Island

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Staten Island University Hospital

OTHER

lead

Northwell Health

OTHER

NCT01876732 - Impact of Vitamin B12 Replacement on Epogen Dosing and Improvement of Quality of Life in Hemodialysis Patients | Biotech Hunter | Biotech Hunter